Topoisomerase II expression

Pu QQ, Bezwoda WR, Alkylator resistance in human B lymphoid cell lines (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line. Anticancer Res 2000 20 2569-22578. 

DNA intercalation mutagenic Induction of cyclin kinase inhibitor p21 inhibition of topoisomerase II expression... 

Shroyer KR, Homer P, Heinz D, et al. Validation of a novel immunocytochemical assay for topoisomerase II- and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006 108 324-330. 

Coutts, J., Plumb, J., Brown, R., and Keith, W. (1993) Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br. J. Cancer 68, 793-800. 

Withoff, S., de Vries, E., Keith, W Nienhuis, E van der Graaf, W Uges, D., and Mulder, N. (1996) Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMS A and mitoxantroneresistant sublines of the human SCLC cell line GFC4. Br. J. Cancer 74,1869-1876. 

Dimov ND, Zynger DL, Luan C, et al. Topoisomerase II alpha expression in testicular germ cell tumors. Urology. 2007 69 955. 

Singh G, Jayanarayan KG, Dey CS. Novobiocin induces apoptosis-like cdl death in topoisomerase II over-expressing arsenite resistant Leishmania donovani. Mol Biochem Parasitol 2005 141 57-69. 

It was observed earlier that over expression of human N-terminal domain in yeast confers resistance to high concentrations of etoposide. The observed phenotype was proposed to be due to the competition of the excess of the N-terminal domain with the frill length enzyme for a limiting pool of inhibitor. So future challenge in the parasite topoisomerase II would be to develop drug resistant parasite strains and to see what causes this resistance and also to check what effect the individual domains of the enzyme have on the drug protein interaction in the context of the full-length enzyme. 

A. PARP-deficfent V79cell line B. V79 cells with NAD unavailability These NAD/PARP-deficient cell lines exhibit a significant reduction in both baseline p53 expression and its activity compared to their parental V79 cells. The topoisomerase II inhibitor etoposide failed to stimulate p53 expression or apoptotic DNA fragmentation in NAD/PARP-deficient cell lines. 36... 

Volm, M., Kiistel, M., Mattern, J., and Efferth, T. (1993). Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 71, 3981-3987. 

---